EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY-NC-ND 4.0

HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial

Md Saiful Alam iD, Laurie W Smith, Lovedeep Gondara, Darrel Cook iD, Ruth Elwood Martin, Stuart Peacock iD, Lily Proctor, Gavin Stuart, David Patrick, Eduardo L Franco iD, Mel Krajden, Anna Gottschlich iD und 1 weitere

International Journal of Cancer · 15.10.2026 · 159 (8) · 2066-2074

DOI: 10.1002/ijc.70616 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Cancer, online erschienen am 27.06.2026. Verfasst von Md Saiful Alam und 12 weiteren Autor:innen. Beteiligte Einrichtung: University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Early Detection of Cancer, Human Papillomavirus Viruses, Papillomavirus Infections, Uterine Cervical Dysplasia. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, CIHR, Michael Smith Health Research BC.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Evidence on the comparative effectiveness of HPV testing versus cytology specifically in women aged ≥ 50 years who are approaching screening cessation remains limited. This analysis included 6471 women aged ≥ 50 at baseline screening in the HPV FOCAL randomized clinical trial. Women were randomly allocated to receive cytology (Control Group, n = 3248, 50.19%) or HPV testing (Intervention Group, n = 3223, 49.81%) at baseline, with co‐testing at 48‐month exit. We calculated incidence rates and risk ratios for CIN2+ detection over follow‐up and compared missed lesions at exit by screening method. At the 48‐month exit, CIN2+ detection was lower among HPV baseline‐negative women than among those in the cytology group (1.61/1000 [95% CI, 0.52–3.76] vs. 3.15/1000 [95% CI, 1.51–5.78]; risk ratio, 0.51 [95% CI, 0.11–0.91]), reflecting higher baseline detection with HPV testing and fewer prevalent lesions at exit. Even with cytology re‐screening at 2 years, 50% of CIN2+ cases were missed compared to 30% with HPV testing. After adjusting for age, education, smoking status, and lifetime sexual partners, the hazard ratio for CIN2+ comparing HPV to cytology was 0.44 (95% CI, 0.22–0.88). Among women aged ≥ 50 years, HPV primary screening was more effective than cytology at detecting CIN2+ lesions and was associated with a continued lower subsequent risk following a negative HPV test, supporting its use in cervical cancer screening programs in this age cohort.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Early Detection of CancerHuman Papillomavirus VirusesPapillomavirus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsAgedFemaleHumansMiddle AgedMass ScreeningPapillomaviridaeVaginal Smears

Stichwörter der Autor:innen

cervical cancer screeningcervical intraepithelial neoplasia (CIN)human papillomavirus (HPV)randomized controlled trialwomen aged 50 and older

Autor:innen und Institutionen

  • University of British Columbia, Vancouver, British Columbia, Canada.
  • Women's Health Research Institute, BC Women's Hospital and Health Service, Vancouver, British Columbia, Canada.
  • British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada.
  • Population Health Sciences, BC Cancer, Vancouver, British Columbia, Canada.
  • Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada.
  • Cervical Screening Program, British Columbia Cancer, Vancouver, British Columbia, Canada.

ORCID-Profile: Md Saiful Alam, Darrel Cook, Stuart Peacock, Eduardo L Franco, Anna Gottschlich, Gina S Ogilvie

Förderung

  • NCI NIH HHS
  • CIHR
  • Michael Smith Health Research BC
  • NIH HHS
  • National Institutes of Health
  • Canadian Institutes of Health Research

Zitieren

APA

Alam, M. S., Smith, L. W., Gondara, L., Cook, D., Martin, R. E., Peacock, S., Proctor, L., Stuart, G., Patrick, D., Franco, E. L., Krajden, M., Gottschlich, A., & Ogilvie, G. S. (2026). HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. International Journal of Cancer, 159(8), 2066-2074. https://doi.org/10.1002/ijc.70616

Vancouver

Alam MS, Smith LW, Gondara L, Cook D, Martin RE, Peacock S, et al. HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial. International Journal of Cancer. 2026;159(8):2066-2074. doi:10.1002/ijc.70616

BibTeX
@article{Alam2026,
  author = {Alam, Md Saiful and Smith, Laurie W and Gondara, Lovedeep and Cook, Darrel and Martin, Ruth Elwood and Peacock, Stuart and Proctor, Lily and Stuart, Gavin and Patrick, David and Franco, Eduardo L and Krajden, Mel and Gottschlich, Anna and Ogilvie, Gina S},
  title = {HPV Testing Versus Cytology for Cervical Cancer Screening Among Women 50 Years and Older: Evidence From the HPV FOCAL Randomized Controlled Trial},
  journal = {International Journal of Cancer},
  year = {2026},
  volume = {159},
  number = {8},
  pages = {2066--2074},
  doi = {10.1002/ijc.70616}
}
Kostenlos starten →